Reaktionsgleichung
Br[C:2]1[CH:20]=[CH:19][C:5]([C:6]([NH:8][C:9]2[CH:18]=[C:17]3[C:12]([CH:13]=[CH:14][CH:15]=[N:16]3)=[CH:11][CH:10]=2)=[O:7])=[CH:4][CH:3]=1.[CH3:21][C:22]1[CH:27]=[CH:26][CH:25]=[C:24]([CH3:28])[C:23]=1B(O)O>>[CH3:21][C:22]1[CH:27]=[CH:26][CH:25]=[C:24]([CH3:28])[C:23]=1[C:2]1[CH:20]=[CH:19][C:5]([C:6]([NH:8][C:9]2[CH:18]=[C:17]3[C:12]([CH:13]=[CH:14][CH:15]=[N:16]3)=[CH:11][CH:10]=2)=[O:7])=[CH:4][CH:3]=1Komponenten
3
Versuchsvorschrift
Using the procedure outlined in Example 58, the title compound was prepared from 4-bromo-N-quinolin-7-ylbenzamide (Example 82) (50 mg, 0.153 mmol) and 2,6-dimethyl-phenylboronic acid (25 mg, 0.17 mmol) as a white solid. 1H NMR (400 MHz, CDCl3) δ (ppm): 8.92 (dd, 1H), 8.20 (d, 1H), 8.14 (m, 3H), 8.02, (d, 2H), 7.87 (d, 1H), 7.37 (dd, 1H), 7.34 (d, 2H), 7.21 (t, 1H), 7.14 (d, 2H), 2.05 (s, 6H).
Quellen und Nachweise
- ORD-Eintrag
- ord-bf000f578d3d41449fd2250791ab27eb
- Quelldatensatz
- uspto-grants-2009_05
- Patentnummer
- US07538121B2
Verknüpfte Notizen
Wird geladen…